


**DISCLOSURE FORM FOR WITNESSES
COMMITTEE ON ARMED SERVICES
U.S. HOUSE OF REPRESENTATIVES**

INSTRUCTION TO WITNESSES: Rule 11, clause 2(g)(5), of the Rules of the House of Representatives for the 118th Congress requires nongovernmental witnesses appearing before House committees to include in their written statements a curriculum vitae and a disclosure of the amount and source of any federal contracts or grants (including subcontracts and subgrants), and contracts or grants (including subcontracts and subgrants), or payments originating with a foreign government, received during the past 36 months either by the witness or by an entity represented by the witness and related to the subject matter of the hearing. Rule 11, clause 2(g)(5) also requires nongovernmental witnesses to disclose whether they are a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing. As a matter of committee policy, the House Committee on Armed Services further requires nongovernmental witnesses to disclose the amount and source of any contracts or grants (including subcontracts and subgrants), or payments originating with any organization or entity, whether public or private, that has a material interest in the subject matter of the hearing, received during the past 36 months either by the witness or by an entity represented by the witness. Please note that a copy of these statements, with appropriate redactions to protect the witness's personal privacy (including home address and phone number), will be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness's appearance before the committee. Witnesses may list additional grants, contracts, or payments on additional sheets, if necessary. Please complete this form electronically.

Hearing Date: 9/16/2024

Hearing Subject:

Fielding Technology and Innovation: Industry Views on Department of Defense Acquisition


Witness name: Mr. Shyam Sankar 

Position/Title: Chief Technology Officer and Executive Vice President

Capacity in which appearing: (check one)

Individual Representative

If appearing in a representative capacity, name of the organization or entity represented: Palantir Technologies Inc.



Federal Contract or Grant Information: If you or the entity you represent before the Committee on Armed Services has contracts (including subcontracts) or grants (including subgrants) with the federal government, received during the past 36 months and related to the subject matter of the hearing, please provide the following information:

2024

Federal grant/ contract	Federal agency	Dollar value	Subject of contract or grant
Please see Disclosure Materials, Attachment A			

2023

Federal grant/ contract	Federal agency	Dollar value	Subject of contract or grant
Please see Disclosure Materials, Attachment A			

2022

Federal grant/ contract	Federal agency	Dollar value	Subject of contract or grant
Please see Disclosure Materials, Attachment A			

2021

Federal grant/ contract	Federal agency	Dollar value	Subject of contract or grant
Please see Disclosure Materials, Attachment			

A			

Foreign Government Contract, Grant, or Payment Information: If you or the entity you represent before the Committee on Armed Services has contracts or grants (including subcontracts or subgrants), or payments originating from a foreign government, received during the past 36 months and related to the subject matter of the hearing, please provide the following information:

2024

Foreign contract/ payment	Foreign government	Dollar value	Subject of contract, grant, or payment
NONE			

2023

Foreign contract/ payment	Foreign government	Dollar value	Subject of contract, grant, or payment
NONE			

2022

Foreign contract/ payment	Foreign government	Dollar value	Subject of contract, grant, or payment
NONE			

2021

Foreign contract/ payment	Foreign government	Dollar value	Subject of contract, grant, or payment
NONE			

Fiduciary Relationships: If you are a fiduciary of any organization or entity that has an interest in the subject matter of the hearing, please provide the following information:

Organization or entity	Brief description of the fiduciary relationship
Palantir Technologies Inc.	Chief Technology Officer and Executive Vice President
Ginkgo Bioworks Holdings, Inc.	Chair of the Board

Organization or Entity Contract, Grant or Payment Information: If you or the entity you represent before the Committee on Armed Services has contracts or grants (including subcontracts or subgrants) or payments originating from an organization or entity, whether public or private, that has a material interest in the subject matter of the hearing, received during the past 36 months, please provide the following information:

2024

Contract/grant/ payment	Entity	Dollar value	Subject of contract, grant, or payment
See footnote (1) below	Palantir Technologies Inc.		
See footnote (2) below	Ginkgo Bioworks Holdings, Inc.		

(1) Please see Disclosure Materials, Attachment A regarding contracts (including subcontracts) or grants (including subgrants) received by Palantir Technologies Inc. (“Palantir”) from the federal government. Please also note that the witness currently serves as the Chief Technology Officer and Executive Vice President of Palantir and receives associated compensation from Palantir. As the fiscal year 2024 is not yet completed, Palantir’s proxy statement covering compensation during such year is not yet available, but, as of the date of this disclosure form, the witness’ compensation is anticipated to be comparable to the compensation disclosed for prior years (please see footnote (3) below for more details).

(2) The witness is not representing Ginkgo Bioworks Holdings, Inc. (“Ginkgo”) before the committee, but, in the interest of full disclosure, please note that Ginkgo has received contracts (including subcontracts) or grants (including subgrants) from the federal government, including from the Department of Defense. Please also note that the witness currently serves as the Chair of the Board of Ginkgo and receives associated compensation from Ginkgo. As the fiscal year 2024 is not yet completed, Ginkgo’s proxy statement covering compensation during such year is not yet available, but, as of the date of this disclosure form, the witness’ compensation is anticipated to be comparable to the

compensation disclosed for prior years (please see footnotes (4), (5) and (6) below for more details).

2023

Contract/grant/ payment	Entity	Dollar value	Subject of contract, grant, or payment
See footnote (3) below	Palantir Technologies Inc.		
See footnote (4) below	Ginkgo Bioworks Holdings, Inc.		

(3) Please see Disclosure Materials, Attachment A regarding contracts (including subcontracts) or grants (including subgrants) received by Palantir from the federal government. Please also note that, the witness currently serves as the Chief Technology Officer and Executive Vice President of Palantir and receives associated compensation from Palantir. For more information regarding such compensation for the fiscal years 2021 to 2023, inclusive, please see Palantir’s proxy statement, as filed with the U.S. Securities and Exchange Commission (“SEC”) on April 26, 2024, which is available here: <https://www.sec.gov/ix?doc=/Archives/edgar/data/1321655/000132165524000059/pltr-20240426.htm>

(4) The witness is not representing Ginkgo before the committee, but, in the interest of full disclosure, please note that Ginkgo has received contracts (including subcontracts) or grants (including subgrants) from the federal government, including from the Department of Defense. Please also note that, the witness currently serves as the Chair of the Board of Ginkgo and receives associated compensation from Ginkgo. For more information regarding such compensation for the fiscal year 2023, please see Ginkgo’s proxy statement, as filed with the SEC on April 29, 2024, which is available here: <https://www.sec.gov/ix?doc=/Archives/edgar/data/1830214/000162828024018970/dna-20240429.htm>

2022

Contract/grant/ payment	Entity	Dollar value	Subject of contract, grant, or payment
See footnote (3) above	Palantir Technologies Inc.		
See footnote (4) above and footnote (5) below	Ginkgo Bioworks Holdings, Inc.		

(5) For more information regarding compensation from Ginkgo for the fiscal year 2022, please see Ginkgo’s proxy statement, as filed with the SEC on April 28, 2023, which is available here: <https://www.sec.gov/ix?doc=/Archives/edgar/data/1830214/000095017023015942/dna-20230428.htm>

2021

Contract/grant/ payment	Entity	Dollar value	Subject of contract, grant, or payment
See footnote (3) above	Palantir Technologies Inc.		
See footnote (4) above and footnote (6) below	Ginkgo Bioworks Holdings, Inc.		

(6) For more information regarding compensation from Ginkgo for the fiscal year 2021, please see Ginkgo's proxy statement, as filed with the SEC on April 26, 2022, which is available here: <https://www.sec.gov/Archives/edgar/data/1830214/000119312522120186/d352792ddef14a.htm>